A New Frontier in the Co-Management of Thyroid Eye Disease

To participate in this activity, please:

Thyroid eye disease, also known as Graves’ orbitopathy, is a potentially serious, progressive autoimmune disease that most often occurs in people with hyperthyroidism, ie, Graves’ disease. Kimberley Cockerham, MD, moderates this series of 6, paired conversations between endocrinologist Terry J. Smith, MD, and eye specialists Wendy W. Lee, MD, and Raymond Douglas, MD, PhD, to explore current and emerging treatment options for thyroid eye disease. In these conversations, faculty review the current understanding of the burden and pathophysiology of thyroid eye disease—including treatment targets—and describe the key features of thyroid eye disease and how they are different from other diseases of the eye. Faculty explore the role of nonpharmacologic, pharmacologic, and surgical options for thyroid eye disease and discuss how to implement strategies that help patients with thyroid eye disease improve their quality of life.

This program is also available as a podcast.  You may download it here: https://anchor.fm/ThyroidEyeDisease

Course Credit:

1.25 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2021-09-29
Closes: 2022-09-29

Target Audience:

This activity was developed for a national audience of endocrinologists, ophthalmologists and other clinicians who diagnose and treat patients with thyroid eye disease (TED).

This activity is supported by an independent educational grant from Horizon Therapeutics.

    Presenting Faculty

  • Kimberly Cockerham, MD

    Adjunct Clinical Associate Professor
    Stanford Department of Ophthalmology
    Central Valley Eye Medical Group
    Modesto, California

  • Raymond Douglas, MD, PhD

    Professor of Surgery
    Division of Ophthalmology
    Director, Orbital and Thyroid Eye Disease Program
    Cedars-Sinai Medical Center
    Los Angeles, California

  • Wendy W. Lee, MD, MS

    Professor of Clinical Ophthalmology and Dermatology
    Director of the Bascom Palmer Aesthetics Center
    Bascom Palmer Eye Institute
    University of Miami Miller School of Medicine
    Miami, Florida

  • Terry J. Smith, MD

    Frederick G.L. Huetwell Professor of Ophthalmology and Visual Sciences
    Professor, Department of Internal Medicine
    Kellogg Eye Center
    Ann Arbor, Michigan

Learning Objectives

  • Describe the current understanding of the pathophysiology of thyroid eye disease, including targets for treatment.
  • Describe key features of thyroid eye disease and how they are different from other diseases involving the eye.
  • Describe the role of nonpharmacologic, pharmacologic, and surgical options for thyroid eye disease.
  • Implement strategies to help patients with thyroid eye disease improve their quality of life.

Faculty Disclosures

Kimberly Cockerham, MD

Consultant: 3T Ophthalmics, Horizon Therapeutics, Viridian

Research support: Horizon Therapeutics


Raymond Douglas, MD, PhD

Consultant: Immunovant, Horizon Therapeutics, Valencia bio, Viridian

Employee: Osmotica

Research Support: Horizon Therapeutics

Speakers Bureau: Horizon Therapeutics


Wendy W. Lee, MD, MS

Consultant: Allergan, Bausch Health, Galderma, Horizon Therapeutics, Mallinckrodt, Osmotica, Revance


Terry J. Smith, MD

Consultant: Horizon Therapeutics

Speakers Bureau: Horizon Therapeutics


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Alex Howsen (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.